Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline PART 05: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 06: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: PIPELINE ANALYSIS PART 09: MARKET SEGMENTATION BY PRODUCT • Overview • Comparison by product • NADs • Antibiotics • Others • Market opportunity by product PART 10: MARKET SEGMENTATION BY DISEASE SEVERITY • Overview • CHE • OHE PART 11: CUSTOMER LANDSCAPE PART 12: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas • EMEA • APAC • Key leading countries • Market opportunity PART 13: DECISION FRAMEWORK PART 14: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 15: MARKET TRENDS • Technological advances • Emergence of novel treatment targets PART 16: VENDOR LANDSCAPE • Overview • Landscape disruption PART 17: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • ASKA Pharmaceutical • COSMO PHARMACEUTICALS • Mallinckrodt • Valeant PART 18: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Interorgan ammonia metabolism in healthy liver Exhibit 02: WHC classification of HE Exhibit 03: Recommended treatment pathway for HE Exhibit 04: Parent market Exhibit 05: Global CNS disorders drugs market: Segments Exhibit 06: Market characteristics Exhibit 07: Global HE therapeutics market: Segments Exhibit 08: Market definition: Inclusions and exclusions checklist Exhibit 09: Market size 2017 Exhibit 10: Validation techniques employed for market sizing 2017 Exhibit 11: Global HE therapeutics market 2017-2022 ($ millions) Exhibit 12: Global HE therapeutics market: Year-over-year growth 2018-2022 (%) Exhibit 13: Five forces analysis 2017 Exhibit 14: Five forces analysis 2022 Exhibit 15: Bargaining power of buyers Exhibit 16: Bargaining power of suppliers Exhibit 17: Threat of new entrants Exhibit 18: Threat of substitutes Exhibit 19: Threat of rivalry Exhibit 20: Market condition: Five forces 2017 Exhibit 21: Pipeline landscape by development phase Exhibit 22: Key clinical trials Exhibit 23: Global HE therapeutics market: Segmentation by product 2017-2022 (%) Exhibit 24: Comparison by product Exhibit 25: Global NAD HE therapeutics market 2017-2022 ($ millions) Exhibit 26: Global NAD HE therapeutics market: Year-over-year growth 2018-2022 (%) Exhibit 27: Global antibiotic HE therapeutics market 2017-2022 ($ millions) Exhibit 28: Global antibiotic HE therapeutics market: Year-over-year growth 2018-2022 (%) Exhibit 29: Global other HE therapeutics market 2017-2022 ($ millions) Exhibit 30: Global other HE therapeutics market: Year-over-year growth 2018-2022 (%) Exhibit 31: Market opportunity by product Exhibit 32: Customer landscape Exhibit 33: Global HE therapeutics market: Segmentation by geography 2017-2022 (%) Exhibit 34: Regional comparison Exhibit 35: HE therapeutics market in Americas 2017-2022 ($ millions) Exhibit 36: HE therapeutics market in Americas: Year-over-year growth 2018-2022 (%) Exhibit 37: HE therapeutics market in EMEA 2017-2022 ($ millions) Exhibit 38: HE therapeutics market in EMEA: Year-over-year growth 2018-2022 (%) Exhibit 39: HE therapeutics market in APAC 2017-2022 ($ millions) Exhibit 40: HE therapeutics market in APAC: Year-over-year growth 2018-2022 (%) Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: ASKA Pharmaceutical: Overview Exhibit 49: ASKA Pharmaceutical: Business segments Exhibit 50: ASKA Pharmaceutical: Organizational developments Exhibit 51: ASKA Pharmaceutical: Segment focus Exhibit 52: ASKA Pharmaceutical: Key offerings Exhibit 53: ASKA Pharmaceutical: Key customers Exhibit 54: COSMO PHARMACEUTICALS: Overview Exhibit 55: COSMO PHARMACEUTICALS: Business segments Exhibit 56: COSMO PHARMACEUTICALS: Organizational developments Exhibit 57: COSMO PHARMACEUTICALS: Segment focus Exhibit 58: COSMO PHARMACEUTICALS: Key offerings Exhibit 59: COSMO PHARMACEUTICALS: Key customers Exhibit 60: Mallinckrodt: Overview Exhibit 61: Mallinckrodt: Business segments Exhibit 62: Mallinckrodt: Organizational developments Exhibit 63: Mallinckrodt: Geographic focus Exhibit 64: Mallinckrodt: Segment focus Exhibit 65: Mallinckrodt: Key offerings Exhibit 66: Mallinckrodt: Key customers Exhibit 67: Valeant: Overview Exhibit 68: Valeant: Business segments Exhibit 69: Valeant: Organizational developments Exhibit 70: Valeant: Geographic focus Exhibit 71: Valeant: Segment focus Exhibit 72: Valeant: Key offerings Exhibit 73: Valeant: Key customers

ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt, and Valeant.